Abstract 191P
Background
Gastric cancer (GC) is a major global health concern, with prognosis influenced by tumor stage and its microenvironment, especially immune cell presence. This research investigates the relation between CD8 T cell expression, emphasizing CXCR6, and GC survival outcomes.
Methods
Using TCGA-STAD RNA-seq data, we studied a cohort of 280 Stage 2 and 3 GC patients. CD8 T cell expression was examined through X Cell Analysis, followed by Cutoff Determination via R package Maxstat. Post categorization into CD8L and CD8H groups, Differential Gene Expression Analysis identified 495 upregulated and 102 downregulated genes. Weighted Gene Co-expression Network Analysis highlighted CXCR6's importance. Correlations between CXCR6, immune cell infiltration, and survival patterns were explored. Verification came from GES 62254 data and Immunohistochemical Staining of a sample from Dong-A University Hospital.
Results
The findings reveal that heightened CXCR6 expression is significantly associated with improved survival outcomes in both recurrence-free survival (RFS) and overall survival (OS) using TCGA-STAD data. Importantly, the validation using GES 62254 data consistently supports these results. Moreover, the study delves into the tumor microenvironment using TCGA-STAD RNA-seq data, showcasing a positive link between CXCR6 expression and immune cell presence, particularly CD8 T cells, T cell gamma delta cells, NK cells, and activated DCs. This suggests a potential reinforcement of anti-tumor responses. The research further uncovers correlations between CXCR6 expression and markers of CD8 T cell activation, as well as the activation of DCs.Importantly, a clinical investigation involving GC patients treated at Dong-A University Hospital supports the statistical significance of increased CXCR6 expression in relation to enhanced survival rates.
Conclusions
Our research showcases the relationship between enhanced CXCR6 expression and improved GC patient survival. It presents CXCR6 as a potential prognostic biomarker, underscoring its role in the tumor immune milieu. The focus on CD8 T cells and immune pathways suggests promising therapeutic directions, marking a step toward precision-based GC interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
National foundation of Korea grant.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract